Phathom Pharmaceuticals Provides Update on FDA Litigation

Phathom faces legal challenges to VOQUEZNA exclusivity, with FDA review ongoing.

What the company is saying

Phathom Pharmaceuticals announces that the FDA has opened a public docket (FDA-2026-N-13038) to gather comments on regulatory questions raised by BDR Pharmaceuticals, an ANDA filer challenging the FDA’s June 6, 2025 decision granting VOQUEZNA 10 years of New Chemical Entity exclusivity through May 3, 2032. The company emphasizes its confidence in the FDA’s review process and its intent to defend its exclusivity position both in submitted comments and in court. Steve Basta, President and CEO, is quoted underscoring the thoroughness of the FDA’s review and Phathom’s commitment to enforcing its statutory rights. Phathom has moved to intervene in the BDR litigation to protect its exclusivities. The company also highlights that a second ANDA filer, Saba Ilac Sanayii Ve Ticaret AS, has filed a notice to potentially consolidate its case with BDR’s. The announcement reiterates Phathom’s exclusive rights to vonoprazan in the U.S., Europe, and Canada, and details the current marketed indications for VOQUEZNA in the United States.

What the data suggests

The FDA’s public docket (FDA-2026-N-13038) is now open for comment on the legal and regulatory issues surrounding VOQUEZNA’s exclusivity, with a deadline of November 23, 2026. The exclusivity period for VOQUEZNA is currently set at 10 years, ending May 3, 2032, as per the FDA’s June 6, 2025 decision. Litigation initiated by BDR Pharmaceuticals seeks to overturn this exclusivity, and Phathom has formally moved to intervene in the case. Saba Ilac Sanayii Ve Ticaret AS has signaled its intent to join the litigation. Phathom’s marketed products include VOQUEZNA tablets for Non-Erosive GERD, Erosive GERD, and as part of DUAL PAK and TRIPLE PAK for H. pylori infection in adults. No financial, sales, or operational performance metrics are disclosed. The announcement provides clear legal and regulatory milestones but omits any quantitative data on product uptake or financial performance.

Analysis

The announcement is a factual update on regulatory and legal proceedings regarding VOQUEZNA's exclusivity status, with no exaggerated or promotional language. Most claims are realised and supported by specific regulatory milestones (FDA docket, exclusivity dates, current marketing status). Forward-looking statements are limited to Phathom's intent to intervene in litigation and the potential consolidation of related cases, but these are procedural rather than aspirational or promotional. No financial or operational performance metrics are disclosed, but this is appropriate given the legal/regulatory focus of the update. There is no mention of capital outlays or promises of future financial benefit, and the tone remains measured. The gap between narrative and evidence is minimal, with all key facts directly supported by the source text.

Risk flags

• ●The exclusivity period for VOQUEZNA is under direct legal challenge by BDR Pharmaceuticals, which could result in a reduction of market exclusivity if the challenge is successful. This would allow generic competition earlier than the current May 3, 2032 end date, potentially impacting revenue and market share.
• ●The FDA’s decision is subject to public comment and further review, introducing regulatory uncertainty. If the FDA reconsiders or reverses its prior decision based on comments or legal outcomes, Phathom’s exclusivity could be shortened.
• ●A second ANDA filer, Saba Ilac Sanayii Ve Ticaret AS, is seeking to consolidate its case with BDR’s, raising the risk of coordinated legal challenges and increasing the complexity and potential cost of litigation.
• ●The litigation process, including possible appeals, may be lengthy, costly, and distracting to management, with uncertain timing and outcomes. Prolonged legal uncertainty could affect investor confidence and business planning.
• ●No financial or sales data is disclosed in the announcement, limiting visibility into the current commercial performance of VOQUEZNA and the potential impact of exclusivity changes on Phathom’s financial position.

Bottom line

Phathom’s regulatory exclusivity for VOQUEZNA is facing active legal and regulatory challenges, with the FDA’s public comment period closing imminently on November 23, 2026. The current exclusivity period runs through May 3, 2032, but this is at risk pending the outcome of litigation and FDA review. The company is taking a proactive legal stance, intervening in the litigation and preparing to defend its position in both regulatory and judicial forums. The involvement of a second ANDA filer signals a growing challenge to exclusivity, increasing the risk of earlier-than-expected generic entry. No operational or financial performance data is provided, so investors cannot assess the current commercial impact of VOQUEZNA or quantify the downside if exclusivity is lost. The most important takeaway is that the exclusivity status for VOQUEZNA is uncertain and may be determined by legal and regulatory outcomes over the coming months to years.

Announcement summary

(NASDAQ:PHAT) Phathom Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has established a public docket (Docket No. FDA-2026-N-13038) to solicit comments on legal and regulatory questions related to issues raised by BDR Pharmaceuticals, International Pvt. Ltd. (BDR), an abbreviated new drug application (ANDA) filer referencing VOQUEZNA® (vonoprazan) tablets, in litigation against the FDA. The litigation challenges the FDA’s June 6, 2025 decision granting Phathom’s Citizen Petition, which confirmed that VOQUEZNA benefits from 10 years of New Chemical Entity (NCE) exclusivity through May 3, 2032. The deadline for submitting comments to the public docket is November 23, 2026. Steve Basta, President and Chief Executive Officer of Phathom, stated that the FDA carefully reviewed the NCE exclusivity period for VOQUEZNA and that Phathom will present its case in comments to the FDA and in any appropriate court proceedings. Phathom has moved to intervene in the litigation filed by BDR to continue enforcing its statutory exclusivities. A second ANDA filer, Saba Ilac Sanayii Ve Ticaret AS, has filed a notice in the BDR litigation, claiming to have a pending related case and intends to move to consolidate its case with BDR’s. Phathom has in-licensed exclusive rights to vonoprazan for the U.S., Europe, and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, for the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults.

Disagree with this article?